GlycoVaxyn, Janssen in vaccine deal
GlycoVaxyn AG (Schlieren, Switzerland) and the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) will use GlycoVaxyn's bio-conjugation technology to develop a multivalent bacterial vaccine. Under the three-year deal, GlycoVaxyn and Janssen's Crucell Holland BV affiliate will collaborate on development until proof-of-concept, after which Janssen will be responsible for further development and worldwide commercialization. GlycoVaxyn will receive an undisclosed upfront payment and is eligible for milestones, plus royalties. The company is also eligible for reimbursement of R&D expenses. GlycoVaxyn's bio-conjugation technology is an in vivo recombinant expression system where vaccines are produced by the synthesis of protein-polysaccharide complexes in Escherichia coli via recombinant DNA technology. The companies could not be reached for details. ...